Comparison of treatment efficacy 1 and 2 years after thyroid remnant ablation with 1110 versus 5550 MBq of iodine-131 in patients with intermediate-risk differentiated thyroid cancer

2017 ◽  
Vol 38 (11) ◽  
pp. 927-931 ◽  
Author(s):  
Atena Aghaei ◽  
Narjess Ayati ◽  
Susan Shafiei ◽  
Bita Abbasi ◽  
S. Rasoul Zakavi
Keyword(s):  
Thyroid Cancer ◽  
Treatment Efficacy ◽  
Differentiated Thyroid Cancer ◽  
Intermediate Risk ◽  
Thyroid Remnant ◽  
Remnant Ablation ◽  
Iodine 131

Lowest effective 131I activity for thyroid remnant ablation of differentiated thyroid cancer patients

2015 ◽  
Vol 54 (03) ◽  
pp. 137-143 ◽  
Author(s):  
A.-S. Moldovan ◽  
M. Ruhlmann ◽  
R. Görges ◽  
A. Bockisch ◽  
S. Rosenbaum-Krumme ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Cancer Patients ◽  
Differentiated Thyroid Cancer ◽  
Absorbed Dose ◽  
Thyroid Remnant ◽  
Remnant Ablation ◽  
Dose Threshold ◽  
131I Activity ◽  
Pet Ct ◽  
Absorbed Radiation Dose

SummaryAim: A theoretical dosimetry-based model was applied to estimate the lowest effective radioiodine activity for thyroid remnant ablation of low-risk differentiated thyroid cancer patients. Patients, methods: The model is based on the distribution of the absorbed (radiation) dose per administered radioiodine activity and the absorbed dose threshold of 300 Gy for thyroid remnants, the level believed to destroy most thyroid remnants. For this purpose, 124I PET/CT images of 49 thyroid-ectomised patients were retrospectively analysed to measure the distribution of the (average) absorbed doses to thyroid remnant per administered 131I activity. The fraction of thyroid remnants that received at least 300 Gy was determined for standard activities between 0.37 and 5.55 GBq. The lower activity was considered to be equally effective to that obtained with higher activity if the (absolute) fraction difference was below 5%. Results: A total of 62 thyroid remnants were included. The medians and ranges (in parentheses) for the absorbed dose per unit 131I activity were 359 Gy/GBq (34 to 1825 Gy/ GBq). The fractions of thyroid remnants receiving more than 300 Gy at different therapy activities (within parentheses) were 60% (1.11 GBq), 76% (1.85 GBq), 79% (2.22 GBq), and 81–82% for activities between 2.59 and 3.70 GBq. The therapy activity of 1.11 GBq is considerably less effective than that of 1.85 or 2.22 GBq; therapy activities were equally effective in the range between 2.22 to 3.70 GBq. Conclusion: On the basis of the model and the patients' data included, the lowest effective therapy activity appears to be approximately 2.2 GBq to ablate thyroid remnants. The results of this study may help to guide the design of prospective clinical studies.

Thyroid remnant ablation in differentiated thyroid cancer

2015 ◽  
Vol 36 (11) ◽  
pp. 1100-1106 ◽  
Author(s):  
Alfredo Campennì ◽  
Luca Giovanella ◽  
Salvatore A. Pignata ◽  
Maria A. Violi ◽  
Massimiliano Siracusa ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Differentiated Thyroid Cancer ◽  
Thyroid Remnant ◽  
Remnant Ablation

Comparison of 800 and 3700 MBq iodine-131 for the postoperative ablation of thyroid remnant in patients with low-risk differentiated thyroid cancer

2012 ◽  
Vol 33 (3) ◽  
pp. 268-274 ◽  
Author(s):  
Meltem Caglar ◽  
Fani M. Bozkurt ◽  
Ceren Kapulu Akca ◽  
Sezen Elhan Vargol ◽  
Miyase Bayraktar ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Differentiated Thyroid Cancer ◽  
Low Risk ◽  
Thyroid Remnant ◽  
Iodine 131

scholarly journals Comparing High and Low-Dose Radio-Iodine Therapy in Thyroid Remnant Ablation Among Intermediate and Low-Risk Papillary Thyroid Carcinoma Patients—Single Centre Experience

Dose-Response ◽  
2021 ◽  
Vol 19 (4) ◽  
pp. 155932582110627
Author(s):  
Tahira Yasmin ◽  
Sadia Adnan ◽  
Muhammad Numair Younis ◽  
Arzoo Fatima ◽  
Abubaker Shahid
Keyword(s):  
Low Dose ◽  
Low Risk ◽  
High Dose ◽  
Intermediate Risk ◽  
Thyroid Remnant ◽  
Remnant Ablation ◽  
Risk Patients ◽  
Iodine 131 ◽  
Disease Free

The role of Iodine-131 therapy is well established as an adjuvant therapy and for thyroid remnant ablation in differentiated thyroid cancer (DTC); however controversy still exists regarding its appropriate dose. Purpose of this study was to compare the effectiveness of low-dose and high-dose Iodine-131 ablation therapies in low- and intermediate-risk PTC patients. Eighty-four patients were divided equally into Group I: Ablated with high dose of Iodine-131 and Group II: Ablated with low dose of Iodine-131. Iodine-131 WBS, serum TG levels and USG neck of all patients were performed at first presentation, 6 months, 1 year, and 2 years follow up. Results are as follows: Group I: 64%, 72%, and 76% intermediate-risk patients were disease free at the follow up intervals of 6 months, 1 year, and 2 years, respectively. Similarly 70%, 82%, and 82% low-risk patients were disease free at above mentioned intervals. Group II: 56%, 60%, and 64% were disease free among intermediate-risk patients while percentage of disease free low-risk patients was 70%, 76%, and 76% at follow up intervals. Low dose of radioactive Iodine-131 was found as effective as high dose in thyroid remnant ablation of PTC patients.

Treatment room length-of-stay and patient throughput with radioiodine thyroid remnant ablation in differentiated thyroid cancer

2011 ◽  
Vol 32 (9) ◽  
pp. 840-846 ◽  
Author(s):  
Juan Antonio Vallejo Casas ◽  
Luisa M. Mena Bares ◽  
María Ángeles Gálvez ◽  
Robert J. Marlowe ◽  
José M. Latre Romero ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Length Of Stay ◽  
Differentiated Thyroid Cancer ◽  
Patient Throughput ◽  
Thyroid Remnant ◽  
Remnant Ablation ◽  
Treatment Room

DELAYED 131-I FIRST TREATMENT AFTER SURGERY HAS NO IMPACT ON THE MEDIAN TERM OUTCOME OF PATIENTS WITH INTERMEDIATE RISK DIFFERENTIATED THYROID CANCER

2020 ◽  
Vol 26 (1) ◽  
pp. 58-71 ◽  
Author(s):  
Antonio Matrone ◽  
Carla Gambale ◽  
Liborio Torregrossa ◽  
Paolo Piaggi ◽  
Francesca Bianchi ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Clinical Outcome ◽  
High Activity ◽  
Differentiated Thyroid Cancer ◽  
Human Thyroid ◽  
American Thyroid Association ◽  
Intermediate Risk ◽  
Remnant Ablation ◽  
Activity Group ◽  
Group A

Objective: In intermediate risk (IR) differentiated thyroid cancer (DTC) patients, selective use of radioiodine (131-I) for remnant ablation and/or as adjuvant therapy (RRA) is advocated. The recently suggested postoperative evaluation could delay the use of RRA. The aim of this study was to evaluate if a delayed RRA can worsen the clinical outcome of IR-DTC patients. Methods: Four hundred and fourteen consecutive IR-DTC patients were divided according to the time elapsed from surgery to RRA, <6 months (group A, 186/414 [44.9%]), or ≥6 months (group B, 228/414 [55.1%]). Clinical and biochemical data were collected, and clinical outcome was analyzed at the first evaluation (EV) after RRA (first-EV) and after a median of 6 years of follow-up (last-EV). Results: No difference in the clinical outcome of group A and B was found. Since a different activity of 131-I could have an impact on the outcome, we separately analyzed the groups according to the 131-I activity (low-activity group: 1,110 MBq/30 mCi [n = 320], and high-activity group: 3,700 MBq/100 mCi [n = 94]), further subdivided according to the time elapsed from surgery to RRA. No major differences were found in both the low- and high-activity groups when comparing the features of their subgroups A and B, as far as in their clinical outcome. Conclusion: The time elapsed between surgery and the first 131-I treatment does not influence the clinical outcome of IR-DTC patients. This finding allows a more relaxed attitude in the decision making process whether to perform the RRA in IR-DTC cases in which a selective use of 131-I is recommended. Abbreviations: ATA = American Thyroid Association; DTC = differentiated thyroid cancer; EV = evaluation; HR = high risk; 131-I = radioiodine; IR = intermediate risk; LR = low risk; rhTSH = recombinant human thyroid-stimulating hormone; RRA = radioiodine for remnant ablation; Tg = thyroglobulin; TgAb = thyroglobulin autoantibody; US = ultrasound

Sign in / Sign up

Export Citation Format

Share Document